← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleRochePhase 3

trastuzumab (Herceptin, Docetaxel combined + Trastuzumab +Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 91.8%임상시험 30상태 RECRUITING
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Docetaxel combined with Trastuzumab±Pertuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 91.8%임상시험 30상태 ACTIVE
AntibodystaleAlliance for Clinical Trials in…Phase 2

Epratuzumab (Epratuzumab)

Lymphoma · Leukemia

#Leukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 DISCONTINUED
AntibodystaleDanish Headache CenterPreclinical

Erenumab (Erenumab)

Migraine; Migraine Without Aura · Migraine

#Migraine#Antibody#Preclinical#항체#면역항체+3
임상시험 30상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 1

nivolumab (Opdivo, Gemcitabine/Carboplatin/Nivolumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#Antibody#Phase1#항체#면역항체+2
효능 ORR 69.6%임상시험 30상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, HER2, pyrotinib + pertuzumab/trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 30상태 RECRUITING
AntibodystaleGrupo Español de Linfomas y Tra…Phase 2

Zevalin (Ibritumomab Tiuxetan, Ibritumomab Tiuxetan (Zevalin))

Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 16%임상시험 30상태 ACTIVE
AntibodystaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 94.1%임상시험 30상태 RECRUITING
AntibodystaleGilead SciencesPhase 2

Magrolimab (Magrolimab)

Solid Tumor; Colorectal Cancer · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.7%임상시험 30상태 DISCONTINUED
AntibodystaleEli Lilly and CompanyPhase 3

Mirikizumab (Mirikizumab)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase3#항체#면역항체+2
효능 ORR 0.115%임상시험 30상태 DISCONTINUED
AntibodystaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#항체#면역항체+5
효능 ORR 25%임상시험 30상태 RECRUITING
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Pertuzumab Plus Trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 69.3%임상시험 30상태 ACTIVE
AntibodystaleRochePreclinical

trastuzumab (Herceptin, Pyrotinib Plus Trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Preclinical#항체#면역항체+2
임상시험 30상태 ACTIVE
AntibodystaleAstraZenecaPhase 3

Ramucirumab+ paclitaxel (Ramucirumab+ paclitaxel)

Gastric Cancer; Gastroesophageal Junction Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase3#항체#면역항체+3
효능 ORR 58.2%임상시험 30상태 RECRUITING
AntibodystaleTG Therapeutics, Inc.Phase 2

Ublituximab (Ublituximab)

Non-Hodgkins Lymphoma; B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 84.4%임상시험 30상태 ACTIVE
AntibodystaleJazz PharmaceuticalsPhase 3

Zanidatamab (Zanidatamab)

HER2-positive Breast Cancer; Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+4
효능 ORR 34%임상시험 30상태 RECRUITING
AntibodystaleJunshi BiosciencesPhase 2

humanized anti-PD-1 monoclonal antibody toripalimab (humanized anti-PD-1 monoclonal antibody toripalimab)

Advanced Melanoma; Metastatic Melanoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 30상태 ACTIVE
AntibodystaleJanssenApproved

teclistamab OR talquetamab OR elranatamab OR linvoseltamab (teclistamab OR talquetamab OR elranatamab OR linvoseltamab)

Waldenstrom Macroglobulinaemia; Multiple Myeloma · Waldenstrom Macroglobulinaemia

#WaldenstromMacroglobulinaemia#Antibody#Approved#항체#면역항체+3
효능 ORR 50%임상시험 30상태 RECRUITING
AntibodystaleEli LillyPhase 2

Toripalimab + cetuximab (3cycles, 3cycles (Toripalimab + cetuximab))

Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 29상태 RECRUITING
AntibodystaleAbbViePhase 3

Budigalimab (Budigalimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#항체#면역항체+2
효능 ORR 14.3%임상시험 29상태 RECRUITING

8 / 62 페이지

← 이전다음 →